

17638
122203**UTILITY PATENT APPLICATION TRANSMITTAL**

(only for new non-provisional applications under 37 CFR §1.53(b))

22264 U.S.P.T.O.
10/743618
122203

U.S. Mail Stop Patent Application
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

December 22, 2003

Date of Deposit

Bennie McEwens
Signature

EL 964822834 US

Express Mail No.

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: USAV2002/0262 US NP

INVENTORS: PAULS, et al.

TITLE: 4-(3-AMINOMETHYLPHENYL)PIPERIDIN-1-YL]-[5-(2-FLUOROPHENYLETHYNYL)FURAN-2-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE

APPLICATION ELEMENTS

- | | | | |
|---|--|--------------|-----------|
| 1. <input checked="" type="checkbox"/> | *Fee Transmittal Form (e.g., PTO/SB/17)
<i>(Submit an original and a duplicate for fee processing)</i> | Total Pages | 38 |
| 2. <input checked="" type="checkbox"/> | Specification
<i>(preferred arrangement set forth below)</i> | Total Sheets | 2 |
| <ul style="list-style-type: none"> - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings <i>(if filed)</i> - Detailed Description - Claim(s) - Abstract of the Disclosure | | | |
| 3. <input type="checkbox"/> | Drawing(s) (35 U.S.C. 113) | Total Sheets | 2 |
| 4. <input type="checkbox"/> | Oath or Declaration | Total Pages | 2 |
| a. <input checked="" type="checkbox"/> | Newly unexecuted (original or copy) | | |
| b. <input type="checkbox"/> | Copy from a prior application (37 CFR § 1.63(d)) | | |
| i. <input type="checkbox"/> | <u>DELETION OF INVENTOR(S)</u>
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b). | | |
| 5. <input type="checkbox"/> | Power of Attorney | Total Pages | 2 |
| a. <input type="checkbox"/> | Newly executed (original or copy) | | |
| b. <input type="checkbox"/> | Copy from a prior application (37 CFR § 1.63(d)) | | |

- If a **CONTINUING Application**, check appropriate box, and supply the requisite information:
 Continuation Divisional Continuation-in-part
of prior application no: _____, filed _____
Examiner _____, Group/Art Unit _____.
(The cross reference has been/will be inserted on page one of the specification).
- This application claims the benefit of U.S. Provisional Application No. 60/436,534, filed December 26, 2002.
- Incorporation By Reference** (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ACCOMPANYING APPLICATION PARTS


6. Assignment Papers (*cover sheet & document(s)*)
7. 37 CFR §3.73(b) Statement
(*when there is an assignee*)
8. Verified English Translation Document (*if applicable*)
9. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
10. Preliminary Amendment
11. Return Receipt Postcard (MPEP 503)
(*Should be specifically itemized*)
12. *Small Entity Statement(s) Statement filed in prior application
(PTO/SB/09-12) Status still proper and desired
13. Certified Copy of Priority Document(s)
(*if foreign priority is claimed*)
14. Other: Application Data Sheet

CORRESPONDENCE ADDRESS

- Customer Number or Bar Code Label

005487

(Insert Customer No. or Attach bar code label here)


Julie Anne Knight, Reg. No. 48,867
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3679
Telefax (908) 231-2626
Aventis Docket No. USAV2002/0262 US NP

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 824.00)

Complete if Known

Application Number	Not Yet Assigned
Filing Date	December 22, 2003
First Named Inventor	PAULS, et al.
Examiner Name	


Group / Art Unit

Attorney Docket No. USAV2002/0262 US NP

METHOD OF PAYMENT (check all that apply)					FEE CALCULATION (continued)				
<input type="checkbox"/> Check <input type="checkbox"/> Credit Card <input type="checkbox"/> Money Order <input type="checkbox"/> Other <input type="checkbox"/> None					3. ADDITIONAL FEES				
<input checked="" type="checkbox"/> Deposit Account					Large Entity Small Entity				
Deposit Account Number: 18-1982 Deposit Account Name: Aventis Pharmaceuticals Inc.					Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
The Commissioner is authorized to: (check all that apply)									
<input checked="" type="checkbox"/> Charge fee(s) indicated below <input checked="" type="checkbox"/> Credit any overpayments									
<input checked="" type="checkbox"/> Charge any additional fee(s) during the pendency of this application									
<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account									
FEE CALCULATION									
1. BASIC FILING FEE									
Large Entity		Small Entity		Fee Description		Fee Paid			
Fee Code	Fee (\$)	Fee Code	Fee (\$)						
1001	770	2001	375	Utility filing fee	770				
1002	340	2002	165	Design filing Fee					
1003	530	2003	260	Plant filing fee					
1004	770	2004	375	Reissue filing fee					
1005	160	2005	80	Provisional filing fee					
SUBTOTAL (1)				(\$770.00)					
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE									
				Extra Claims	Fee from below	Fee Paid			
Total Claims	23	-20**=	3	x 18	= 54				
Independent	1	- 3**=	0	x 0	= 0				
Claims									
Multiple Dependent				0	= 0				
Large Entity		Small Entity		Fee Description					
Fee Code	Fee (\$)	Fee Code	Fee (\$)						
1202	18	2202	9	Claims in excess of 20					
1201	86	2201	42	Independent claims in excess of 3					
1203	290	2203	140	Multiple dependent claim, if not paid					
1204	86	2204	42	**Reissue independent claims over original patent					
1205	18	2205	9	**Reissue claims in excess of 20 and over original patent					
SUBTOTAL (2)				(\$54.00)					
*or number previously paid, if greater; For Reissues, see above									
Other fee (specify) _____									
*Reduced by Basic Filing Fee Paid									
SUBTOTAL (3) (\$)									

SUBMITTED BY

Complete (If applicable)

Name (Print/Type)	Julie Anne Knight, Reg. No. 48,867	Registration No. (Attorney/Agent)	48,867	Telephone	(908) 231-3679
Signature				Date	12/18/03

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.